Guardant Health, Inc. (BMV:GH)
Mexico · Delayed Price · Currency is MXN | Market Cap | 396.93B +243.9% |
| Revenue (ttm) | 19.47B +39.6% |
| Net Income | -7.81B |
| EPS | -61.38 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10 |
| Open | 2,590.00 |
| Previous Close | n/a |
| Day's Range | 2,590.00 - 2,590.00 |
| 52-Week Range | 1,150.00 - 2,590.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Guardant Health
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transc... [Read more]
Financial Performance
In 2025, Guardant Health's revenue was $982.02 million, an increase of 32.88% compared to the previous year's $739.02 million. Losses were -$416.28 million, -4.61% less than in 2024.
Financial numbers in USD Financial StatementsNews
Guardant Health Shield blood test now covered by UnitedHealth
Guardant Health (GH) announced its Shield blood test for colorectal cancer screening is now covered for eligible UnitedHealth (UNH) Group members, which the company says makes it “the first major…
UnitedHealth Group Now Covers Guardant Health's Shield Blood Test for Colorectal Cancer Screening
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) is now covere...
Guardant Health price target raised to $190 from $160 at BTIG
BTIG raised the firm’s price target on Guardant Health (GH) to $190 from $160 and keeps a Buy rating on the shares. The shares are rising today on the back…
Citi says UnitedHealth coverage for Shield ‘another positive step’ for Guardant
Citi views United Healthcare (UNH) announcing coverage for the Shield CRC screening test, starting August 1, as “another positive catalyst” for Shield and Guardant Health (GH). This expansion of the…
Guardant rallies after UnitedHealth covers colorectal cancer test
Shares of Guardant Health (GH) are moving higher after UnitedHealth (UNH) announced coverage for the company’s Guardant Shield, a blood-based colorectal cancer screening. Guardant is up 7%, or $10.61,...
Guardant Health price target raised to $160 from $135 at Guggenheim
Guggenheim raised the firm’s price target on Guardant Health (GH) to $160 from $135 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select…
Guardant Health resumed with an Outperform at Bernstein
Bernstein resumed coverage of Guardant Health (GH) with an Outperform rating and $175 price target following a return from maternity leave. “Many things” are going right for the life science…
Guardant Health price target raised to $150 from $120 at Barclays
Barclays raised the firm’s price target on Guardant Health (GH) to $150 from $120 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science…
Living Longer Is Big Business. These Stocks Will Benefit.
TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.
Guardant Health Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation approvals, with all proposals passing by majority vote. No questions were raised by stockholders, and final results will be filed with the SEC.
Gamehost Receives Final Court Order Authorizing Sale to Pure Casino Entertainment
Not intended for distribution to U.S. newswire services or for dissemination in the U.S. Red Deer, Alberta--(Newsfile Corp. - June 15, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that the C...
Gamehost Shareholders Approve Sale to Pure Casino Entertainment
Red Deer, Alberta--(Newsfile Corp. - June 12, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that its shareholders (the "Gamehost Shareholders") have approved its previously announced transact...
Guardant Health initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of Guardant Health (GH) with an Outperform rating and $185 price target The firm cites the company’s “structural growth, near-term catalysts, and meaningful average sell...
Guardant Health announces U.S. FDA approved Guardant360 CDx
Guardant Health (GH) announced that the U.S. Food and Drug Administration, FDA, has approved Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim’s Hernexeos, the first targeted therapy ...
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360®...
Guardant Health management to meet with Piper Sandler
Meeting to be held in New York on June 16 hosted by Piper Sandler.
Guardant Health price target raised to $175 from $135 at Mizuho
Mizuho raised the firm’s price target on Guardant Health (GH) to $175 from $135 and keeps an Outperform rating on the shares. The firm says the company’s recent 360 and…
Guardant Health initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Guardant Health (GH) with a Buy rating and $165 price target The company has seral near term growth drivers, including the recent FDA approval of…
Guardant Health Transcript: Jefferies Global Healthcare Conference 2026
Q1 2026 saw record revenue and volume growth, driven by oncology and screening momentum, new product launches, and expanded collaborations. ACS guidelines and FDA approvals are set to boost future volumes and reimbursement, while commercial scaling and AI-driven innovation support long-term profitability and competitive strength.
Guardant Health Transcript: 46th Annual William Blair Growth Stock Conference
Strong innovation and commercial execution are driving rapid revenue growth, with multiple products addressing large oncology and screening markets. Shield’s adoption is accelerating, supported by guideline inclusion and strategic partnerships, while financial discipline positions the business for sustained profitability and cash flow breakeven by 2027.
Guardant Health Slides: 46th Annual William Blair Growth Stock Conference
Guardant Health has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Guardant Health upgraded to Outperform from In Line at Evercore ISI
Evercore ISI upgraded Guardant Health (GH) to Outperform from In Line with a price target of $160, up from $95. G360 ADLT pricing of $8,455 should lead to average selling…
Guardant Health assumed with an Outperform at Wolfe Research
Wolfe Research analyst Paige Chamberlain assumed coverage of Guardant Health (GH) with an Outperform rating and price target of $150, up from $120. Wolfe names Guardant its top idea in…
Guardant Health to present 38 abstracts at ASCO 2026 meeting
Guardant Health (GH) announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer (PFE), showcasing advances in methylati...
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstrac...